FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304872> ?p ?o ?g. }

• W4367304872 abstract "<h3>Objective:</h3> This post hoc analysis evaluated treatment response to lower-sodium oxybate (LXB; Xywav®) on Epworth Sleepiness Scale (ESS) and Idiopathic Hypersomnia Severity Scale (IHSS) scores in a phase 3 clinical trial (NCT03533114). <h3>Background:</h3> Idiopathic hypersomnia is a debilitating neurologic sleep disorder characterized by excessive daytime sleepiness, with sleep inertia and prolonged nighttime sleep as key symptoms in many patients. <h3>Design/Methods:</h3> Eligible participants with idiopathic hypersomnia began LXB treatment in an open-label titration and optimization period (OLT; 10–14 weeks), followed by a 2-week, open-label, stable-dose period (SDP). The ESS and IHSS were completed at baseline, OLT week (W)1, W4, W8, end of OLT, and end of SDP, and response (ESS score ≤10 or decrease in ESS score of ≥4 points; IHSS score ≤22 or decrease in IHSS score of ≥4) was assessed. <h3>Results:</h3> Participants were treatment naive (n=47) or taking alerting agents at study entry (n=62). Among treatment-naive participants, the percentages achieving ESS score ≤10, ESS score decrease of ≥4 points, IHSS score ≤22, and IHSS score decrease of ≥4 points at W1 and end of SDP were, respectively, 13.0% and 87.2%, 26.1% and 87.2%, 26.1% and 80.9%, and 45.7% and 93.6%. Among participants taking alerting agents, the percentages achieving the same responses at W1 and end of SDP were, respectively, 21.0% and 83.9%, 33.9% and 95.2%, 24.2% and 82.3%, and 46.8% and 98.4%. Treatment-emergent adverse events (≥10%) included nausea, headache, dizziness, anxiety, and vomiting. <h3>Conclusions:</h3> Over 80% of participants achieved clinically meaningful responses on the ESS and IHSS; up to 95% (ESS) and 98% (IHSS) had score decreases ≥4 points at end of SDP. Response rate increased over the course of the study. The safety profile of LXB was consistent with that observed in narcolepsy. <b>Disclosure:</b> Mr. Rosenberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Mr. Rosenberg has received research support from Neurotrials Research. Ms. Chen has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Chen has received stock or an ownership interest from Jazz Pharmaceuticals. Teresa Steininger has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Teresa Steininger has stock in Jazz Pharmaceuticals. Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has stock in Jazz pharma. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel." @default.
• W4367304872 created "2023-04-29" @default.
• W4367304872 creator A5028786504 @default.
• W4367304872 creator A5039137167 @default.
• W4367304872 creator A5046553734 @default.
• W4367304872 creator A5082868877 @default.
• W4367304872 creator A5088488166 @default.
• W4367304872 date "2023-04-25" @default.
• W4367304872 modified "2023-09-26" @default.
• W4367304872 title "Efficacy of Low-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Treatment Response Based on the Epworth Sleepiness Scale and Idiopathic Hypersomnia Severity Scale Scores (S6.009)" @default.
• W4367304872 doi "https://doi.org/10.1212/wnl.0000000000202229" @default.
• W4367304872 hasPublicationYear "2023" @default.
• W4367304872 type Work @default.
• W4367304872 citedByCount "0" @default.
• W4367304872 crossrefType "proceedings-article" @default.
• W4367304872 hasAuthorship W4367304872A5028786504 @default.
• W4367304872 hasAuthorship W4367304872A5039137167 @default.
• W4367304872 hasAuthorship W4367304872A5046553734 @default.
• W4367304872 hasAuthorship W4367304872A5082868877 @default.
• W4367304872 hasAuthorship W4367304872A5088488166 @default.
• W4367304872 hasConcept C126322002 @default.
• W4367304872 hasConcept C15744967 @default.
• W4367304872 hasConcept C1862650 @default.
• W4367304872 hasConcept C197934379 @default.
• W4367304872 hasConcept C2778205975 @default.
• W4367304872 hasConcept C2778664715 @default.
• W4367304872 hasConcept C2779034229 @default.
• W4367304872 hasConcept C2781326671 @default.
• W4367304872 hasConcept C67761136 @default.
• W4367304872 hasConcept C71924100 @default.
• W4367304872 hasConceptScore W4367304872C126322002 @default.
• W4367304872 hasConceptScore W4367304872C15744967 @default.
• W4367304872 hasConceptScore W4367304872C1862650 @default.
• W4367304872 hasConceptScore W4367304872C197934379 @default.
• W4367304872 hasConceptScore W4367304872C2778205975 @default.
• W4367304872 hasConceptScore W4367304872C2778664715 @default.
• W4367304872 hasConceptScore W4367304872C2779034229 @default.
• W4367304872 hasConceptScore W4367304872C2781326671 @default.
• W4367304872 hasConceptScore W4367304872C67761136 @default.
• W4367304872 hasConceptScore W4367304872C71924100 @default.
• W4367304872 hasLocation W43673048721 @default.
• W4367304872 hasOpenAccess W4367304872 @default.
• W4367304872 hasPrimaryLocation W43673048721 @default.
• W4367304872 hasRelatedWork W1143323492 @default.
• W4367304872 hasRelatedWork W149901548 @default.
• W4367304872 hasRelatedWork W1976189538 @default.
• W4367304872 hasRelatedWork W2028283308 @default.
• W4367304872 hasRelatedWork W2076214385 @default.
• W4367304872 hasRelatedWork W2082445982 @default.
• W4367304872 hasRelatedWork W2139148584 @default.
• W4367304872 hasRelatedWork W2414561605 @default.
• W4367304872 hasRelatedWork W2546004130 @default.
• W4367304872 hasRelatedWork W4280521716 @default.
• W4367304872 isParatext "false" @default.
• W4367304872 isRetracted "false" @default.
• W4367304872 workType "article" @default.